Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03974022




Registration number
NCT03974022
Ethics application status
Date submitted
21/05/2019
Date registered
4/06/2019
Date last updated
16/05/2024

Titles & IDs
Public title
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Scientific title
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
Secondary ID [1] 0 0
DZ2019E0001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sunvozertinib

Experimental: Part A Dose escalation -

Experimental: Part A Dose expansion cohort 1 -

Experimental: Part A Dose expansion cohort 2 -

Experimental: Part A Dose expansion cohort 3 - Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy

Experimental: Part A Dose expansion cohort 4 - Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy

Experimental: Part A Dose expansion cohort 5 - Patients with EGFR Exon20ins, treatment naïve

Experimental: Part A Dose expansion cohort 6 -

Experimental: Part B Dose extension cohort 1 - Patients with EGFR Exon20ins

Experimental: Part B Dose extension cohort 2 - Patients with EGFR Exon20ins


Treatment: Drugs: Sunvozertinib
Daily dose of Sunvozertinib
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Safety and tolerability of Sunvozertinib.
Timepoint [1] 0 0
28 days after the first multiple dose
Primary outcome [2] 0 0
Part B: Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC).
Timepoint [2] 0 0
through the study completion, an average of around 1 year
Secondary outcome [1] 0 0
Part A: Plasma and urine Sunvozertinib concentrations, and derived PK parameters.
Timepoint [1] 0 0
Through cycle 3 day 1 (8 days for Cycle 0, 28 days for Cycle 1, then 21 days for each subsequent cycle)
Secondary outcome [2] 0 0
Part A: Plasma Sunvozertinib concentrations, and derived PK parameters
Timepoint [2] 0 0
Through the study completion
Secondary outcome [3] 0 0
Part A: ORR, BOR, DoR, DCR, %change in size of tumor lesion, PFS by investigator.
Timepoint [3] 0 0
Through the study completion
Secondary outcome [4] 0 0
Part A: ORR, DCR, DoR by IRC.
Timepoint [4] 0 0
Through the study completion
Secondary outcome [5] 0 0
Part B: DoR, PFS, DCR, BOR and % of change in size of tumor lesion according to RECIST 1.1 using assessments performed by an IRC; DoR, PFS, DCR, BOR and % of change in size of tumor lesion using investigators assessments accord.
Timepoint [5] 0 0
Through the study completion
Secondary outcome [6] 0 0
Part B: AEs/SAEs; Laboratory data; vital signs; physical examination; ECG; echocardiogram/MUGA; pulmonary function test.
Timepoint [6] 0 0
Through the study completion
Secondary outcome [7] 0 0
Part B: Plasma Sunvozertinib and metabolite concentration and derived PK parameters if deemed appropriately.
Timepoint [7] 0 0
Through the study completion

Eligibility
Key inclusion criteria
1. Aged at least 18 years old, be able to provide a signed and dated, written informed
consent.

2. With documented histological or cytological confirmed locally advanced or metastatic
NSCLC with EGFR or HER2 mutations.

3. (ECOG) performance status 0-1.

4. Predicted life expectancy = 12 weeks

5. Patient must have measurable disease according to RECIST 1.1.

6. Patients with brain metastasis (BM) can be enrolled under the condition that BM is
previously treated and stable, neurologically asymptomatic and does not require
corticosteroid treatment.

7. Adequate organ system function.

8. Part A Dose expansion: Dose expansion cohort 5: NSCLC patients with EGFR Exon20ins,
who have not received prior systemic therapy (treatment naïve).

Part B Dose extension:

9. Patients must have histologically or cytologically confirmed locally advanced or
metastatic NSCLC with documented EGFR Exon20ins mutation in tumor tissue from a local
CLIA-certified laboratory (or equivalent) or Sponsor designated central laboratory
prior to the study entry.

10. Patients should have received at least 1 line, but no more than 3 lines of systemic
therapy for metastatic/locally advanced disease.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. For part B: Patients who have received prior treatment with Poziotinib or TAK788 or
other EGFR/HER2 exon20 insertion inhibitors should be excluded. Prior treatment with
currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as
gefitinib, erlotinib, osimertinib, afatinib and dacomitinb, are allowed unless the
patient had an objective response and subsequent progression assessed by the
investigator.

2. Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular
access), or onco-immunotherapy (e.g. immune checkpoint inhibitors PD-1, PD-L1, CTLA-4)
within 4 weeks before the first administration of Sunvozertinib.

3. Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a
previous treatment regimen or clinical study within 14 days before the first
administration.

4. Radiotherapy with a limited field of radiation for palliation within 1 week of the
first dose or with a wide field of radiation which must be completed within 4 weeks
before the first administration.

5. Receiving (or unable to stop using) medications or herbal supplements known to be
potent inhibitors or inducers of CYP3A within 1-2 weeks before the first
administration.

6. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of
starting Sunvozertinib with the exception of alopecia and grade 2 prior
platinum-therapy related neuropathy.

7. Spinal cord compression or leptomeningeal metastasis.

8. As judged by the investigator, any evidence of severe or uncontrolled systemic
diseases, which would jeopardize compliance with the protocol, or active infection
including hepatitis B, hepatitis C, human immunodeficiency virus (HIV) and COVID-19
(per local practice).

9. Any of the following cardiac criteria: (1) Mean resting corrected QT interval (QTc) >
470 msec obtained from 3 electrocardiograms (ECGs); (2) Any clinically significant
abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left
bundle branch block, third degree heart block, and second-degree heart block, PR
interval > 250 msec. (3) Any factors that increase the risk of QTF prolongation, such
as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT
syndrome or unexplained sudden death under 40 years of age in first degree relatives
or any concomitant medication known to prolong the QT interval; (4) Prior history of
atrial fibrillation within 6 months of first administration of Sunvozertinib, except
prior drug treatment related and recovered.

10. Past medical history of interstitial lung disease, drug-induced interstitial lung
disease, radiation pneumonitis which required steroid treatment, or any evidence of
clinically active interstitial lung disease.

11. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
swallow the formulated product or previous significant bowel resection that would
preclude adequate absorption of Sunvozertinib.

12. History of hypersensitivity to active or inactive excipients of Sunvozertinib or drugs
with a similar chemical structure or class to Sunvozertinib.

13. Women who are pregnant or breast feeding.

14. Involvement in the planning and conduct of the study.

15. Judgment by the investigator that the patient should not participate in the study if
the patient is unlikely to comply with study procedures, restrictions and
requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/07/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2025
Actual
Sample size
Target
Accrual to date
Final
315
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Blacktown Hospital - Blacktown
Recruitment hospital [2] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [4] 0 0
St George Hospital - Kogarah
Recruitment hospital [5] 0 0
Peter MacCallum Cancer Centre - East Melbourne - North Melbourne
Recruitment hospital [6] 0 0
Linear Cancer trials - Perth
Recruitment hospital [7] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment postcode(s) [1] 0 0
- Blacktown
Recruitment postcode(s) [2] 0 0
- Camperdown
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment postcode(s) [4] 0 0
- Kogarah
Recruitment postcode(s) [5] 0 0
- North Melbourne
Recruitment postcode(s) [6] 0 0
- Perth
Recruitment postcode(s) [7] 0 0
- Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
Argentina
State/province [9] 0 0
Cabildo
Country [10] 0 0
Argentina
State/province [10] 0 0
Ciudad Autónoma Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Pergamino
Country [12] 0 0
Argentina
State/province [12] 0 0
Viedma
Country [13] 0 0
Canada
State/province [13] 0 0
Toronto
Country [14] 0 0
Chile
State/province [14] 0 0
Providencia
Country [15] 0 0
Chile
State/province [15] 0 0
Santiago
Country [16] 0 0
Chile
State/province [16] 0 0
Temuco
Country [17] 0 0
China
State/province [17] 0 0
Beijing
Country [18] 0 0
China
State/province [18] 0 0
Changchun
Country [19] 0 0
China
State/province [19] 0 0
Changsha
Country [20] 0 0
China
State/province [20] 0 0
Chengdu
Country [21] 0 0
China
State/province [21] 0 0
Chongqing
Country [22] 0 0
China
State/province [22] 0 0
Fuzhou
Country [23] 0 0
China
State/province [23] 0 0
Guangzhou
Country [24] 0 0
China
State/province [24] 0 0
Haikou
Country [25] 0 0
China
State/province [25] 0 0
Hangzhou
Country [26] 0 0
China
State/province [26] 0 0
Harbin
Country [27] 0 0
China
State/province [27] 0 0
Hefei
Country [28] 0 0
China
State/province [28] 0 0
Henan
Country [29] 0 0
China
State/province [29] 0 0
Hohhot
Country [30] 0 0
China
State/province [30] 0 0
Huai'an
Country [31] 0 0
China
State/province [31] 0 0
Jinan
Country [32] 0 0
China
State/province [32] 0 0
Linyi
Country [33] 0 0
China
State/province [33] 0 0
Nanchang
Country [34] 0 0
China
State/province [34] 0 0
Nanning
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
China
State/province [36] 0 0
Shenyang
Country [37] 0 0
China
State/province [37] 0 0
Taiyuan
Country [38] 0 0
China
State/province [38] 0 0
Taizhou
Country [39] 0 0
China
State/province [39] 0 0
Tianjin
Country [40] 0 0
China
State/province [40] 0 0
Wuhan
Country [41] 0 0
China
State/province [41] 0 0
Xi'an
Country [42] 0 0
China
State/province [42] 0 0
Zhengzhou
Country [43] 0 0
France
State/province [43] 0 0
Angers
Country [44] 0 0
France
State/province [44] 0 0
Bron
Country [45] 0 0
France
State/province [45] 0 0
Dijon
Country [46] 0 0
France
State/province [46] 0 0
Hellemmes Lille
Country [47] 0 0
France
State/province [47] 0 0
Marseille
Country [48] 0 0
France
State/province [48] 0 0
Montpellier
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Poitiers
Country [51] 0 0
France
State/province [51] 0 0
Saint-Herblain
Country [52] 0 0
France
State/province [52] 0 0
Saint-Mandé
Country [53] 0 0
France
State/province [53] 0 0
Toulouse
Country [54] 0 0
France
State/province [54] 0 0
Villejuif
Country [55] 0 0
Italy
State/province [55] 0 0
Aviano
Country [56] 0 0
Italy
State/province [56] 0 0
Catania
Country [57] 0 0
Italy
State/province [57] 0 0
Firenze
Country [58] 0 0
Italy
State/province [58] 0 0
Meldola
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Parma
Country [61] 0 0
Italy
State/province [61] 0 0
Ravenna
Country [62] 0 0
Italy
State/province [62] 0 0
Reggio Emilia
Country [63] 0 0
Italy
State/province [63] 0 0
Roma
Country [64] 0 0
Japan
State/province [64] 0 0
Matsuyama-shi
Country [65] 0 0
Japan
State/province [65] 0 0
Nagoya-Shi
Country [66] 0 0
Japan
State/province [66] 0 0
Niigata-Shi
Country [67] 0 0
Japan
State/province [67] 0 0
Okayama-Shi
Country [68] 0 0
Japan
State/province [68] 0 0
Tokushima-Shi
Country [69] 0 0
Japan
State/province [69] 0 0
Tokyo
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Cheonju
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Goyang
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Seongnam
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Seoul
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Suwon
Country [75] 0 0
Malaysia
State/province [75] 0 0
Johor Bahru
Country [76] 0 0
Malaysia
State/province [76] 0 0
Kuala Lumpur
Country [77] 0 0
Spain
State/province [77] 0 0
Barcelona
Country [78] 0 0
Spain
State/province [78] 0 0
Girona
Country [79] 0 0
Spain
State/province [79] 0 0
Jerez de la Frontera
Country [80] 0 0
Spain
State/province [80] 0 0
Madrid
Country [81] 0 0
Spain
State/province [81] 0 0
Malaga
Country [82] 0 0
Spain
State/province [82] 0 0
Sevilla
Country [83] 0 0
Spain
State/province [83] 0 0
Valencia
Country [84] 0 0
Taiwan
State/province [84] 0 0
Liuying
Country [85] 0 0
Taiwan
State/province [85] 0 0
Taichung
Country [86] 0 0
Taiwan
State/province [86] 0 0
Tainan
Country [87] 0 0
Taiwan
State/province [87] 0 0
Taipei
Country [88] 0 0
Taiwan
State/province [88] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Dizal Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have
progressed following prior therapy. This is the first time this drug is tested in patients,
and so it will help to understand what type of side effects may occur with the drug
treatment. It will also measure the levels of drug in the body and preliminarily assess its
anti-cancer activity as monotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03974022
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pasi Antero Jänne, M.D & Ph. D
Address 0 0
Dana-Farber Cancer Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03974022